IC
IOVA icon

IEQ Capital’s Iovance Biotherapeutics IOVA Stock Holding History

IEQ Capital’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.22M Buy
292,962
+273,758
+1,426% +$1.04M 0.01% 1024
2026
Q1 		$67.4K Buy
+19,204
New +$61.4K ﹤0.01% 1830

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

IEQ Capital's IOVA Position: Q2 2026 in Review

IEQ Capital increased its Iovance Biotherapeutics (IOVA) stake by 1,426% in Q2 2026, buying an estimated $1.04M and bringing the position to 292,962 shares worth $1.22M. The position accounts for 0.01% of the portfolio, ranked #1024.

IEQ Capital first reported a position in IOVA in Q1 2026 and has held it in 2 quarters since. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • IEQ Capital held 292,962 shares of Iovance Biotherapeutics worth $1.22M as of Q2 2026.
  • IEQ Capital bought 273,758 Iovance Biotherapeutics shares in Q2 2026, an estimated $1.04M.
  • Iovance Biotherapeutics made up 0.01% of IEQ Capital's portfolio in Q2 2026, its #1024 holding.
  • IEQ Capital first reported a position in Iovance Biotherapeutics in Q1 2026 and has held it in 2 quarters since.
  • 292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on IEQ Capital's 13F filing for Q2 2026, filed 11 Aug 2026.